• Alias: AC220
    • An orally available small molecule that selectively inhibits class III RTKs, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and PDGFR
    • Phase 2 and 3 trials in FLT3-ITD–positive and FLT3-ITD–negative acute myelogenous leukemia
    • Dose: 30 to 60 mg PO daily (continuous dosing)
    • Half-life: â™1.5 days
    • Side effects: Nausea/vomiting/diarrhea, prolonged QTc, anorexia/dysgeusia, fatigue, hypocalcemia
    (Cortes et al., 2013)
    Other topics in Targeted and Immunotherapy Agents